S Aebi
Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity
Hamzic S, Kummer D, Milesi S, Mueller D, Jörger M, Aebi S, Amstutz U, Largiader C. Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity. Clin Pharmacol Ther 2017; 102:796-804.
30.05.2017Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity
30.05.2017Clin Pharmacol Ther 2017; 102:796-804
Hamzic S, Kummer D, Milesi S, Mueller D, Jörger Markus, Aebi S, Amstutz U, Largiader C R
Spotlight on pomalidomide: could less be more?
Zander T, Aebi S, Pabst T, Renner C, Driessen C. Spotlight on pomalidomide: could less be more?. Leukemia 2017; 31:1987-1989.
22.05.2017Spotlight on pomalidomide: could less be more?
22.05.2017Leukemia 2017; 31:1987-1989
Zander T, Aebi S, Pabst T, Renner C, Driessen Christoph
Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, Moos R, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller T, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99. Ann Oncol 2016
19.12.2016Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized Phase III trial SAKK 22/99
19.12.2016Ann Oncol 2016
Pagani O, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann Beat, Moos R von, Zaman K, Goldhirsch A, Pestalozzi B, Munzone E, Klingbiel D, Ruhstaller Thomas, Nolé F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess Dagmar, Mamot C
The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity
Hamzic S, Wenger N, Froehlich T, Jörger M, Aebi S, Largiader C, Amstutz U. The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity. Pharmacogenomics J 2016
22.03.2016The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity
22.03.2016Pharmacogenomics J 2016
Hamzic S, Wenger N, Froehlich T K, Jörger Markus, Aebi S, Largiader C R, Amstutz U
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
Strasser F, Koeberle D, Kaasa S, Mauri S, Haefner M, Brauchli P, Klingbiel D, Hayoz S, Betticher D, Aebi S, Ribi K, Cathomas R, von Moos R, Blum D, Swiss Group for Clinical Cancer Research (SAKK). The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06). Ann Oncol 2015
08.12.2015The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)
08.12.2015Ann Oncol 2015
Strasser Florian, Koeberle D, Kaasa S, Mauri S, Haefner M, Brauchli P, Klingbiel D, Hayoz S, Betticher D, Aebi S, Ribi K, Cathomas R, von Moos R, Blum D, Swiss Group for Clinical Cancer Research (SAKK)
Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
Feilchenfeldt J, Jochum W, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Diebold J, Khanfir K, Varga Z, Siano M, Grabsch H, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Hofer S. Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). Br J Cancer 2015; 113:716-21.
27.08.2015Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
27.08.2015Br J Cancer 2015; 113:716-21
Feilchenfeldt J, Jochum Wolfram, Shoji H, Kushima R, Wagner D, Shimada Y, Cats A, Knuth A, Moch H, Aebi S, Diebold J, Khanfir K, Varga Z, Siano Marco, Grabsch H I, Held U, Schuknecht B, Trip A, Hamaguchi T, Gut P, Balague O, Hofer S
Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
Zaman K, Aebi S, Brauchli P, Genton C, Berthod G, Giobbie-Hurder A, Simcock M, Lüthi J, Pagani O, Schonenberger A, Huober J, Thürlimann B, on behalf of the Swiss Group for Clinical Cancer Research (SAKK). Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Ann Oncol 2011
14.10.2011Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
14.10.2011Ann Oncol 2011
Zaman K, Aebi S, Brauchli P, Genton C, Berthod G, Giobbie-Hurder A, Simcock M, Lüthi J, Pagani O, Schonenberger A, Huober Jens, Thürlimann Beat, on behalf of the Swiss Group for Clinical Cancer Research (SAKK)
The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up
Colleoni M, Goldhirsch A, Price K, Viale G, Aebi S, Cinieri S, Peccatori F, Green M, Gelber R, Coates A, Basser R, Martinelli G, Sun Z, International Breast Cancer Study Group. The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol 2009; 20:1344-51.
01.08.2009The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up
01.08.2009Ann Oncol 2009; 20:1344-51
Colleoni M, Goldhirsch A, Price K N, Viale G, Aebi S, Cinieri S, Peccatori F, Green M D, Gelber R D, Coates A S, Basser R L, Martinelli G, Sun Z, International Breast Cancer Study Group
Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
Bernhard J, Coates A, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Colleoni M, Green M, Thürlimann B, Yeo W, Aebi S, Forbes J, Hürny C, Basser R, Martinelli G, Zhang J, Zahrieh D, International Breast Cancer Study Group. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. BJC 2008; 98:25-33.
15.01.2008Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
15.01.2008BJC 2008; 98:25-33
Bernhard J, Coates A S, Goldhirsch A, Price K N, Castiglione-Gertsch M, Gelber R D, Colleoni M, Green M D, Thürlimann Beat, Yeo W, Aebi S, Forbes J F, Hürny C, Basser R, Martinelli G, Zhang J J, Zahrieh D, International Breast Cancer Study Group
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
Keshaviah A, Coates A, Gelber R, Castiglione Gertsch M, Simoncini E, Pagani O, Price K, Aebi S, Mendiola C, Thürlimann B, Colleoni M, Collins J, Crivellari D, Lindtner J, Rotmensz N, Dellapasqua S, Goldhirsch A. CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials. Ann Oncol 2007; 18:701-8.
01.04.2007CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials
01.04.2007Ann Oncol 2007; 18:701-8
Keshaviah A, Coates A S, Gelber R D, Castiglione Gertsch M, Simoncini E, Pagani O, Price K N, Aebi S, Mendiola C, Thürlimann Beat, Colleoni M, Collins J, Crivellari D, Lindtner J, Rotmensz N, Dellapasqua S, Goldhirsch A
Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
Hess D, Goldhirsch A, Castiglione-Gertsch M, Rufener B, Ballabeni P, Rauch D, Aebi S, Pagani O, Thürlimann B, Swiss Group of Clinical Cancer Research (SAKK). Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004; 15:1760-5.
01.12.2004Capecitabine and vinorelbine in elderly patients (> or =65 years) with metastatic breast cancer: a phase I trial (SAKK 25/99)
01.12.2004Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004; 15:1760-5
Hess Dagmar, Goldhirsch A, Castiglione-Gertsch M, Rufener B, Ballabeni P, Rauch D, Aebi S, Pagani O, Thürlimann Beat, Swiss Group of Clinical Cancer Research (SAKK)
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
Aebi S, Coates A, Werner I, Simoncini E, Cortes-Funes H, Crivellari D, Lindtner J, Rudenstam C, Thürlimann B, Collins J, Gelber R, Castiglione-Gertsch M, Gelber S, Goldhirsch A. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. Lancet 2000; 355:1869-74.
27.05.2000Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
27.05.2000Lancet 2000; 355:1869-74
Aebi S, Coates A S, Werner I D, Simoncini E, Cortes-Funes H, Crivellari D, Lindtner J, Rudenstam C M, Thürlimann Beat, Collins J, Gelber R D, Castiglione-Gertsch M, Gelber S, Goldhirsch A
Analgesic action of i.v. morphine-6-glucuronide in healthy volunteers
Buetler T, Wilder-Smith O, Wilder-Smith C, Aebi S, Cerny T, Brenneisen R. Analgesic action of i.v. morphine-6-glucuronide in healthy volunteers. British journal of anaesthesia 2000; 84:97-9.
01.01.2000Analgesic action of i.v. morphine-6-glucuronide in healthy volunteers
01.01.2000British journal of anaesthesia 2000; 84:97-9
Buetler T M, Wilder-Smith O H, Wilder-Smith C H, Aebi S, Cerny Thomas, Brenneisen R